Man Group
RNAM

Man Group’s Avidity Biosciences RNAM Stock Holding History

Man Group’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-898,277
Closed -$64.8M – 2548
2025
Q4 		$64.8M Buy
898,277
+868,827
+2,950% +$56.1M 0.11% 192
2025
Q3 		$1.28M Buy
29,450
+12,127
+70% +$490K ﹤0.01% 1582
2025
Q2 		$492K Sell
17,323
-132,932
-88% -$3.96M ﹤0.01% 1837
2025
Q1 		$4.44M Sell
150,255
-272,166
-64% -$8.48M 0.01% 1074
2024
Q4 		$12.3M Sell
422,421
-487,710
-54% -$20.4M 0.03% 653
2024
Q3 		$41.8M Buy
+910,131
New +$39.5M 0.11% 241
2023
Q3 		– Sell
-27,800
Closed -$240K – 1844
2023
Q2 		$308K Buy
+27,800
New +$349K ﹤0.01% 1717
2023
Q1 		– Sell
-60,200
Closed -$1.34M – 2221
2022
Q4 		$1.34M Buy
+60,200
New +$898K ﹤0.01% 1229

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $158M AUM

Man Group's RNAM Position: Q1 2026 in Review

Man Group sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 898,277 shares — an estimated $64.8M sold.

Man Group first reported a position in RNAM in Q4 2022 and held it in 8 quarters. The position peaked at $64.8M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Man Group reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Man Group sold 898,277 Avidity Biosciences shares in Q1 2026, an estimated $64.8M.
  • Man Group first reported a position in Avidity Biosciences in Q4 2022 and held it in 8 quarters.
  • Man Group's Avidity Biosciences position peaked at $64.8M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.